Orally Disintegrating Tablets Market Key Highlights:
- Market Size (2024): USD 17.63 Billion
- Projected Market Size (2034): USD 53.79 Billion
- CAGR (2023-2034): 11.8%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Orally Disintegrating Tablets Market
The orally disintegrating tablets market is an important branch of the pharmaceutical industry. This industry deals in the manufacturing and distribution of orally disintegrating tablets around the world. There are various types of drug classes available in the market, such as anxiolytics, anti-allergic drugs, proton pump inhibitors, and some others. The rise in the number of clinical trials, along with enhanced drug bioavailability, has positively impacted industrial growth. This market is likely to rise significantly with the growth of the healthcare industry across the world.
The growing demand for anti-psychotics, anti-epileptics, and anti-hypertensives across the world has boosted the market expansion. Also, the rising incidences of neurological disorders, gastrointestinal diseases, allergic diseases, cardiovascular disorders, and some others are impacting the market growth. Moreover, the increasing availability of these tablets in several platforms, such as hospital pharmacies, drug stores, retail pharmacies, online pharmacies, and some others, is expected to boost the growth of the orally disintegrating tablets market.
Advancements in the ODT industry, along with growing investment in developing better quality orally disintegrating tablets, are expected to create ample growth opportunities for the market players in the future. In July 2024, Adalvo launched Desmopressin. Desmopressin is an oral disintegrating tablet used in the treatment of primary nocturnal enuresis, diabetes insipidus, and nocturia.
Orally Disintegrating Tablets Market Segmentation:
By Type
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
By Application
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
Orally Disintegrating Tablets Market Companies:
- Teva
- Merck
- Mylan
- Pfizer
- Johnson and Johnson
- GSK
- Otsuka
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Conquer.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
